News
HEPA
1.380
-7.38%
-0.110
S&P 500 Rises Over 1%; Zions Bancorp Shares Gain After Q1 Earnings
U.S. Stocks traded higher toward the end of trading on Monday. The Dow traded up 1.02% and the S&P 500 gained more than 1%. Financial shares climbed by 1.3% on Monday after Zions Bancorporation reported upbeat earnings. Moolec Science SA shares shot up 63% after receiving USDA approval for plant-grown animal proteins.
Benzinga · 1d ago
Why Is Liver-Disease Drug Developer Hepion Pharmaceuticals Stock Trading Lower On Monday?
Hepion Pharmaceuticals Inc. Said it has begun winding down activities in its ASCEND-NASH trial. The company is continuing to explore strategic alternatives. Hepion is testing rencofilstat for the treatment of NASH in a Phase 2b study. There were no safety concerns observed in the trial.
Benzinga · 1d ago
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Vaxxinity, Inc. (NASDAQ:VAXX) fell sharply during Monday's mid-day session. The company announced its intention to voluntarily delist and deregister its Class A common stock. Matterport, Inc., shares jumped 184% to $4.93.
Benzinga · 1d ago
MRIN, WISA and SMFL among mid-day movers
On the Move MRIN, WISA and SMFL among mid-day movers in SA. Matterport, mF International and Edible Garden AG are among the Gainers. YY Group Holding Limited is one of the losers in SA's top 10 list of companies.
Seeking Alpha · 2d ago
12 Health Care Stocks Moving In Monday's Intraday Session
NKGen Biotech (NASDAQ:NKGN) shares rose 33.8% to $1.48 during Monday's regular session. The company's, Q4 earnings came out 4 days ago. MSP Recovery shares rose 29.74% and Assure Hldgs stock increased by 24.31%. Losers include Vaxxinity, Ocean Biomedical and Telomir Pharmaceuticals.
Benzinga · 2d ago
Nike Layoffs 2024: What to Know About the Latest Nike Job Cuts
Nike layoffs will result in 740 employees at the company’s Beaverton, Ore., headquarters losing their jobs. The athletic apparel company announced plans to cut jobs at its global headquarters in February. Nike stock is down slightly on Monday morning after the company announced the latest round of layoffs. Tesla, Hepion Pharmaceuticals and Vaxxinity are also in the news today.
Investorplace · 2d ago
Dow Jumps Over 100 Points; Chicago Fed National Activity Rises In March
U.S. Stocks traded higher on Monday, with the Dow Jones gaining over 100 points. The Dow traded up 0.31% to 38,104.99 while the NASDAQ rose 0.62%. The Chicago Fed National Activity Index increased to +0.15 in March. Information technology shares climbed by 0.8% on Monday. Asian markets closed mostly higher in Asia Pacific markets.
Benzinga · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-Verizon, Tesla, Vista Outdoor
U.S. Stocks poised to open higher on Monday. Easing Middle East tensions buoyed risk appetite. Dow e-minis up 0.56% at 38,421.75. Top three NYSE percentage gainers: Brunswick Corp, KB Financial, Vista Outdoor. Tesla down 4.3% premarket.
Reuters · 2d ago
Why Is Hepion Pharmaceuticals (HEPA) Stock Down 41% Today?
Hepion Pharmaceuticals (NASDAQ:HEPA) stock is diving on Monday after the biopharmaceutical company announced plans to wind down a clinical trial. The company is failing to reach the planned 336 patients for its NASH study. With this news comes a 40.5% drop for HEPA stock on Monday morning. Vaxxinity stock, OLB Group stock and Moolec Science stock are also down today. InvestorPlace offers insight into the top stock market news for Monday.
Investorplace · 2d ago
SBFM, BPTH and INDO among pre-market losers
On the Move SBFM, BPTH and INDO among pre-market losers. Hepion Pharmaceuticals -38% initiates wind-down activities in Phase 2b ‘ASCEND-NASH’ trial. Terronera surpasses 50% construction completion.
Seeking Alpha · 2d ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Adial Pharmaceuticals (NASDAQ:ADIL) stock rose 34.2% to $2.59 during Monday's pre-market session. NKGen Biotech and T2 Biosystems moved upwards. Vaxxinity stock declined by 61.3% during the session.
Benzinga · 2d ago
BUZZ-U.S. STOCKS ON THE MOVE-EV stocks, Salesforce, Verizon
U.S. Stock index futures gain on Monday after slumping in the previous session. Easing Middle East tensions buoyed risk sentiment. Investors look ahead to major tech earnings and a key inflation print this week. Tesla shares fall after the company cuts prices. Salesforce up 3.4% in premarket.
Reuters · 2d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Moolec Science stock is rocketing more than 67% on approval for its plant-groan animal proteins. Vaxxinity stock is crashing more than 55% on the company's plans to delist its shares. The biggest pre-market stock movers for Monday morning are earnings, investments, a delisting and more.
Investorplace · 2d ago
Weekly Report: what happened at HEPA last week (0415-0419)?
Weekly Report · 2d ago
Hepion Pharma Shares Plunge 31% After Disclosing Plans to Wind Down Trial
Shares of Hepion Pharmaceuticals dropped in post-market on Friday. The company announced plans to wind down its Ascend-Nash trial due to resource constraints. The stock tumbled 31% to $1.39. The shares closed the day's regular session down 4.8%. Hepion is down 38% this year.
Dow Jones · 4d ago
BUZZ-Hepion tumbles after discontinuing trial for fatty liver disease treatment
Shares of drug developer Hepion Pharmaceuticals fall 33.8% to $1.30 in extended trading. Company says it is winding down a mid-stage trial for treatment of a fatty liver disease. Company is continuing to explore strategic alternatives. Hepion's stock down 86.4% in last 12 months.
Reuters · 4d ago
Hepion ends Phase 2 study for NASH drug due to cash restraints
Seeking Alpha · 4d ago
Hepion Pharmaceuticals Says Co "Remains Committed To Its Strategic Alternative Efforts Previously Announced In Dec 2023. Given The Number Of Enrolled NASH Patients To Date And The Low Probability Of Generating Relevant Efficacy Data To Support A Registrational Trial With Our Current Cash Resources, We Have Opted To Wind Down The Program And Assure That Patients Are Transitioned Out Of The Trial In A Safe And Compliant Manner"
Hepion announces the wind-down of its Phase 2 NASH trial. The company says there were no safety concerns observed for rencofilstat in the ASCEND-NASH trial. Hepion says the company remains committed to its strategic alternative efforts to treat NASH.
Benzinga · 4d ago
More
Webull provides a variety of real-time HEPA stock news. You can receive the latest news about Hepion Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About HEPA
Hepion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development of drug therapy for treatment of chronic liver diseases. This therapeutic approach targets fibrosis, inflammation, and the treatment hepatocellular carcinoma (HCC) associated with non-alcoholic steatohepatitis (NASH), viral hepatitis and other liver diseases. The Company's cyclophilin inhibitor, rencofilstat is developed to offer benefits to address multiple complex pathologies relate to advanced liver disease. The Company’s rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease. The Company provides an artificial intelligence (AI) tool, AI-POWR, that allows the selection of novel drug targets, biomarkers, and appropriate patient populations. The components of AI-POWR include access to publicly available databases, and in-house genomic and multi-omic big.